Welcome to Francis Academic Press

Academic Journal of Medicine & Health Sciences, 2024, 5(4); doi: 10.25236/AJMHS.2024.050409.

Research Progress on the Mechanism of Salvia Miltiorrhiza Extract Inhibiting Platelet Aggregation


Wang Haixia1, Dai Yinhai2, Yang Yifan3, Peng Tao1, Yan Yongmei3, Wang Tao4

Corresponding Author:
Wang Tao

1Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China

2The Second Affiliated Hospital of Shaanxi University of Chinese Medicine, Xianyang, Shaanxi, 712046, China

3Affiliated Hospital of Shaanxi University of Traditional Chinese Medicine, Xianyang, Shaanxi, 712046, China

4Shaanxi Provincial People's Hospital, Xi'an, Shaanxi, 710068, China


Thrombotic diseases have high disability rates, high mortality rates, and seriously endanger human health and safety. Platelets play an important role in the process of thrombus formation. Salvia miltiorrhiza has been widely recognized in clinical practice both domestically and internationally for its ability to promote blood circulation, remove blood stasis, antioxidant, and anti-platelet aggregation, and anti-atherosclerosis effects. Due to the multi-component, multi-pathway, and multi-target characteristics of the anti-platelet aggregation mechanism of Salvia miltiorrhiza, the specific signal transduction pathway has become a hot and difficult research topic in studying the pharmacological mechanism of Salvia miltiorrhiza. Based on the latest literature, this article reviews the targets and pathways of the modern pharmacological mechanism of Salvia miltiorrhiza extract in anti-platelet aggregation, providing new ideas for the research of safer and more effective anti-platelet aggregation drugs.


thrombotic diseases; salvia miltiorrhiza extract; anti-platelet aggregation; thrombosis; signaling pathway

Cite This Paper

Wang Haixia, Dai Yinhai, Yang Yifan, Peng Tao, Yan Yongmei, Wang Tao. Research Progress on the Mechanism of Salvia Miltiorrhiza Extract Inhibiting Platelet Aggregation. Academic Journal of Medicine & Health Sciences (2024), Vol. 5, Issue 4: 64-70. https://doi.org/10.25236/AJMHS.2024.050409.


[1] Mackman N. Triggers, targets and treatments for thrombosis [J]. Nature, 2008, 451(7181):914-918.

[2] Shatzel J J, O'Donnell M, Olson S R, et al. Venous thrombosis in unusual sites: A practical review for the hematologist [J]. European Journal of Haematology, 2018, 102(1):53-62.

[3] Kamran H, Jneid H, Kayani W T, et al. Oral Antiplatelet Therapy After Acute Coronary Syndrome: A Review[J]. JAMA, 2021, 325(15): 1545-1555.

[4] Wang L, Ma R, Liu C, et al. Salvia miltiorrhiza: A Potential Red Light to the Development of Cardiovascular Diseases [J]. Current Pharmaceutical Design, 2017, 23(7): 1077-1097.

[5] Wang J, Xu J, Gong X, et al. Biosynthesis, Chemistry, and Pharmacology of Polyphenols from Chinese Salvia Species: A Review[J]. Molecules (Basel, Switzerland), 2019, 24(1): 155.

[6] Naghavi M, Abajobir A A, Abbafati C, et al. Global, regional, and national age-sex specific mortality for 264 causes of death, 1980–2016: a systematic analysis for the Global Burden of Disease Study 2016[J]. The Lancet, 2017, 390(10100):1151-1210.

[7] Yang D, Ma P, Liang X, et al. Metabolic profiles and cDNA-AFLP analysis of Salvia miltiorrhiza and Salvia castanea Diel f. tomentosa Stib[J]. PloS One, 2012, 7(1): e29678.

[8] Bai X, Wang X, Xu Q. Endothelial damage and stem cell repair in atherosclerosis[J]. Vascular Pharmacology, 2010, 52(5-6):224-229.

[9] Gremmel T, Frelinger A, Michelson A. Platelet Physiology[J]. Seminars in Thrombosis and Hemostasis, 2016, 42(03):191-204.

[10] Xia F, Lin L S, Ye Y S, et al. 11,12-seco-Abietane-type diterpene lactones with potential antiplatelet activity from Salvia prattii[J]. Bioorganic Chemistry, 2023, 140: 106834.

[11] Zhao X, Cooper M, Michael J V, et al. GRK2 regulates ADP signaling in platelets via P2Y1 and P2Y12[J]. Blood Advances, 2022,6(15):4524-4536.

[12] Wu L, Zhao F, Dai M, et al. P2y12 Receptor Promotes Pressure Overload-Induced Cardiac Remodeling via  Platelet-Driven Inflammation in Mice[J]. Hypertension, 2017, 70(4):759-769.

[13] Mackman N, Bergmeier W, Stouffer G A, et al. Therapeutic strategies for thrombosis: new targets and approaches [J]. Nature reviews. Drug discovery, 2020,19(5):333-352.

[14] Li S, Wang W, Lin L, et al. Oligosaccharide Blocks PAR1 (Proteinase-Activated Receptor 1)-PAR4-Mediated Platelet Activation by Binding to Thrombin Exosite II and Impairs Thrombosis [J]. Arteriosclerosis, Thrombosis, and Vascular Biology, 2023, 43(2): 253-266.

[15] Fuentes E, Gibbins J M, Holbrook L M, et al. NADPH oxidase 2 (NOX2): A key target of oxidative stress-mediated platelet  activation and thrombosis[J]. Trends Cardiovasc Med, 2018,28(7):429-434.

[16] Chen Q, Wang Q, Zhu J, et al. Reactive oxygen species: key regulators in vascular health and diseases [J]. Br J Pharmacol, 2018, 175(8):1279-1292.

[17] Pastori D, Pignatelli P, Carnevale R, et al. Nox-2 up-regulation and platelet activation: Novel insights[J]. Prostaglandins & Other Lipid Mediators, 2015, 120: 50-55.

[18] Li Y P, Wang C Y, Shang H T, et al. A high-throughput and untargeted lipidomics approach reveals new mechanistic insight and the effects of salvianolic acid B on the metabolic profiles in coronary heart disease rats using ultra-performance liquid chromatography with mass spectrometry[J]. RSC advances, 2020, 10(29): 17101-17113.

[19] Chen J, Wang Y, Wang S, et al. Salvianolic acid B and ferulic acid synergistically promote angiogenesis in HUVECs and zebrafish via regulating VEGF signaling[J]. Journal of Ethnopharmacology, 2022, 283: 114667.

[20] Liu L, Li J, Zhang Y, et al. Salvianolic acid B inhibits platelets as a P2Y12 antagonist and PDE inhibitor: Evidence from clinic to laboratory[J]. Thrombosis Research, 2014, 134(4):866-876.

[21] Blann A D, Draper Z. Platelet activation as a marker of heart attack[J]. Clinica chimica acta, 2011, 412(11-12):841-842.

[22] Guo R, Li L, Su J, et al. Pharmacological Activity and Mechanism of Tanshinone IIA in Related Diseases[J]. Drug Design, Development and Therapy, 2020, 14: 4735-4748.

[23] Maione F, De Feo V, Caiazzo E, et al. Tanshinone IIA, a major component of Salvia milthorriza Bunge, inhibits platelet activation via Erk-2 signaling pathway[J]. Journal of Ethnopharmacology, 2014, 155(2): 1236-1242.

[24] Simmonds M P M S. Rosmarinic acid[J]. Phytochemistry, 2003,62(2):121-125.

[25] Frickel E, Frei P, Bouvier M, et al. ERp57 Is a Multifunctional Thiol-Disulfide Oxidoreductase[J]. Journal of Biological Chemistry, 2004, 279(18):18277-18287.

[26] Jasuja R, Passam F H, Kennedy D R, et al. Protein disulfide isomerase inhibitors constitute a new class of antithrombotic agents[J]. Journal of Clinical Investigation, 2012,122(6):2104-2113.

[27] Zou J, Chen Y, Hoi M P M, et al. Discovery of a Novel ERp57 Inhibitor as Antiplatelet Agent from Danshen(Salvia miltiorrhiza)[J]. Evidence-Based Complementary and Alternative Medicine, 2018, 2018: 1-9.

[28] Holbrook L M, Sasikumar P, Stanley R G, et al. The platelet‐surface thiol isomerase enzyme ERp57 modulates platelet function[J]. Journal of Thrombosis and Haemostasis, 2012, 10(2): 278-288.

[29] Zhang J, Zhang Q, Liu G, et al. Therapeutic potentials and mechanisms of the Chinese traditional medicine Danshensu[J]. European Journal of Pharmacology, 2019, 864: 172710.

[30] Cui G, Shan L, Guo L, et al. Novel anti-thrombotic agent for modulation of protein disulfide isomerase family member ERp57 for prophylactic therapy[J]. Scientific Reports, 2015, 5: 10353.

[31] Xue Y, Zhang L, Zhang L, et al. Danshensu prevents thrombosis by inhibiting platelet activation via SIRT1/ROS/mtDNA pathways without increasing bleeding risk [J]. Phytomedicine, 2022, 104:154271.

[32] Leprán I, Lefer A M. Protective actions of propyl gallate, a lipoxygenase inhibitor, on the ischemic myocardium [J]. Circulatory Shock, 1985, 15(2): 79-88.

[33] Huang M, Pang W, Zhang J, et al. A target analogue imprinted polymer for the recognition of antiplatelet active ingredients in Radix Salviae Miltiorrhizae by LC/MS/MS[J]. Journal of Pharmaceutical and Biomedical Analysis, 2012, 58: 12-18.

[34] Huang M, Pang W, Zhang J, et al. A target analogue imprinted polymer for the recognition of antiplatelet active ingredients in Radix Salviae Miltiorrhizae by LC/MS/MS[J]. Journal of Pharmaceutical and Biomedical Analysis, 2012, 58:12-18.

[35] Stefanini L, Roden R C, Bergmeier W. CalDAG-GEFI is at the nexus of calcium-dependent platelet activation [J]. Blood, 2009, 114(12):2506-2514.

[36] Park J, Lee S, Yang M, et al. 15, 16-Dihydrotanshinone I, a major component from Salvia miltiorrhiza Bunge (Dansham), inhibits rabbit platelet aggregation by suppressing intracellular calcium mobilization [J]. Archives of Pharmacal Research, 2008, 31(1):47-53.

[37] Li S, Wang N, Hong M, et al. Hepatoprotective Effects of a Functional Formula of Three Chinese Medicinal Herbs: Experimental Evidence and Network Pharmacology-Based Identification of Mechanism of Action and Potential Bioactive Components[J]. Molecules (Basel, Switzerland), 2018, 23(2): 352.

[38] Zhang X, Zhang P, An L, et al. Miltirone induces cell death in hepatocellular carcinoma cell through GSDME-dependent pyroptosis[J]. Acta Pharmaceutica Sinica. B, 2020, 10(8): 1397-1413.

[39] Zhou L, Jiang L, Xu M, et al. Miltirone exhibits antileukemic activity by ROS-mediated endoplasmic reticulum stress and mitochondrial dysfunction pathways[J]. Scientific Reports, 2016, 6: 20585.

[40] Song W, Ma Y Y, Miao S, et al. Pharmacological actions of miltirone in the modulation of platelet function [J]. Acta Pharmacol Sin, 2019, 40(2):199-207.